As another example, a phase II trial, in which the combinatorial administration of 17-AAG (tanespimycin) plus trastuzumab displayed significant anti-cancer activity in patients with Her-2-positive metastatic breast cancer, which was previously seen to progress on trastuzumab [148]. Here, ERBB2 is linked to cancer.